Prosecution Insights
Last updated: September 17, 2026
Application No. 18/000,102

PREPARATION METHOD FOR (S)-2-AMINO-3-(4-(2,3-DIMETHYLPYRIDIN-4-YL)PHENYL)METHYL PROPIONATE DIACID SALT

Final Rejection §Other
Filed
Jul 17, 2023
Priority
May 28, 2020 — CN 202010481657.X +1 more
Examiner
ANDERSON, REBECCA L
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd.
OA Round
2 (Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
763 granted / 1040 resolved
+13.4% vs TC avg
Strong +24% interview lift
Without
With
+23.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
47 currently pending
Career history
1092
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
18.7%
-21.3% vs TC avg
§102
24.1%
-15.9% vs TC avg
§112
33.0%
-7.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1040 resolved cases

Office Action

§Other
DETAILED ACTION Claims 1-8 are currently pending and are allowed. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I in the reply filed on 21 January 2026 has been previously acknowledged. Response to Amendment and Arguments Applicant's amendment and arguments filed 23 July 2026 have been fully considered and entered into the instant application. Applicant’s amendment to the specification has overcome the objection to the specification for lacking page numbers, however, the amendment has introduced new matter into the specification and the specification is still objected. Applicant’s amendment has overcome the objection to claims 1-3 and 6. Applicant’s amendment has overcome the 35 USC 112(b) rejections of claims 1-8. Specification The amendment filed 23 July 2026 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure. 35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: “, each of which is herein incorporated by reference in its entirety.” See MPEP 211.02: PNG media_image1.png 436 788 media_image1.png Greyscale While applicant provided specific reference to the prior application(s) in the application data sheet filed 28 November 2022, which is reflected on the Official Filing Receipt dated 25 July 2023, this is considered an incorporation by reference as to inadvertently omitted material subject to the conditions and requirements of 37 CFR 1.57(b), which provides a safeguard for applicants when all or a portion of the specification and/or drawing(s) is (are) inadvertently omitted from an application. Applicant is also encouraged at the time of filing to provide in the specification an explicit incorporation by reference statement to the prior filed application(s) for which benefit is claimed, if applicant does not wish the incorporation by reference to be limited to inadvertently omitted material. Applicant’s application filed 26 May 2021, did not include an explicit incorporation by reference statement in the specification. Applicant’s amendment filed 23 July 2026 adds an incorporation by reference statement as follows: “, each of which is herein incorporated by reference in its entirety” which is added after the application’s filing date. An incorporation by reference statement added after an application’s filing date is not effective because no new matter can be added to an application after its filing date. Applicant is required to cancel the new matter in the reply to this Office Action. Closest Prior Art The closest prior art is CN102378574B (IDS 12/20/2022, cite no. 005 Foreign Patent Documents) which is discussed in the background of the invention in the instant specification. CN102378574B discloses the process PNG media_image2.png 222 728 media_image2.png Greyscale see paragraph [1411]-[1415] which differs from the claimed process: PNG media_image3.png 272 776 media_image3.png Greyscale , for example, as formula I is not utilized in the prior art process to prepare formula IV which is utilized to prepare formula V of the instant claims. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 4 September 2026 Rebecca Anderson Primary Examiner Art Unit 1626, Group 1620 Technology Center 1600
Read full office action

Prosecution Timeline

Jul 17, 2023
Application Filed
Apr 24, 2026
Non-Final Rejection mailed — §Other
Jul 23, 2026
Response Filed
Sep 09, 2026
Final Rejection mailed — §Other (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735385
ALKYLSULFENYL THIOCARBONATES: PRECURSORS TO HYDROPERSULFIDES POTENTLY ATTENUATE OXIDATIVE STRESS
2y 10m to grant Granted Sep 15, 2026
Patent 12729196
N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
3y 2m to grant Granted Sep 08, 2026
Patent 12715864
PROCESS FOR THE SYNTHESIS OF N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1- YLMETHYLPHENYL)-5-ISO-BUTYLTHIOPHENE-2-SULFONAMIDE
3y 9m to grant Granted Aug 25, 2026
Patent 12703706
ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE
3y 2m to grant Granted Aug 11, 2026
Patent 12692233
ANTHELMINTIC COMPOUNDS COMPRISING A PYRIDINE STRUCTURE
3y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+23.6%)
2y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1040 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month